Universitè De Montpellier

Institut National De La Sante Et De La Recherche Medicale

Centre National De La Recherche Scientifique

Centre Hospitalier Universitaire De Montpellier

Université D'auvergne

Université´ D'aix-Marseille

Université Paul Sabatier (toulouse Iii)

Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement

Ecole Nationale Superieure De Chimie De Montpellier

Centre Hospitalier Universitaire De Toulouse

Institut De Recherche Pour Le Developpement (ird)

Université Cote D'azur

Centre National De La Recherche Scientifique-cnrs

Inserm (institut National De La Sante Et De La Recherche Medicale)

Université Clermont Auvergne

Thierry Durand

Céline Crauste

Joseph Vercauteren

Philippe Brabet

Christian Hamel

David Cia

Claire Vigor

Laurent Guillou

Eric Oswald

Patricia Martin

Francisco Veas

Teresa Perez-Berezo

Jean-Marie Galano

Justine Bertrand-Michel

Nicolas Cenac

Nicolas Blondeau

Pauline Le Faouder

Alexandre Guy

Espérance Moine

Julien Pujo

The invention relates to compound of formula (I): in particular flavonoid derivatives (quercetin and catechin derivatives), for use in the prevention and/or the treatment of a disease or disorder involving both carbonyl and oxidative stresses.

Lipophenolic flavonoid derivatives useful to reduce carbonyl and oxidative stresses (COS)

The invention is based on the discovery of a new bacterial compound with analgesic properties which could be used as a new tool for the treatment of pain disorders such as visceral pain. Studying the mechanisms implicated in analgesic properties of the probioticstrain Nissle 1917 (EcN), inventors characterized, the amino fatty acids produced by EcN, which display the Ecn analgesic properties. One of these compounds inhibits the hypersensitivity to colorectal distension induced by capsaicin, which is a very powerful nociceptive compound and acts via the GABA B receptor. Furthermore, inventors demonstrate that this compound is able to cross the cellular epithelial barrier (such as the intestinal epithelium). Thus, the invention relates to a lipopetide compound, derived from gamma-aminobutyric acid. The invention also relates to a lipopeptide compound according to the invention for the treatment of treating pain disorder, such as somatic pain and visceral pain.

Lipopeptide compounds for the treatment of pain disorders

The present invention relates to compound of formula (I): whereinR is O&#x2014;Ror Rand Rare identical or different and are each independently H, (C-C)alkyl, &#x2014;CO&#x2014;(C-C)alkyl or &#x2014;CO&#x2014;(C-C)alkenyl group, provided that at least one of Ror Ris H or (C-C)alkyl,Ris a &#x2014;CO&#x2014;(C-C)alkyl or &#x2014;CO&#x2014;(C-C)alkenyl group,or its pharmaceutically acceptable salts, racemates, diastereoisomers, enantiomers, or mixtures thereof,for use in prevention and/or treatment of a disease or disorder linked to an exacerbated vascular, lymphatic or mucosal permeability.

Uses of lipophenolic compounds

The present invention relates to a compound of formula (I) wherein: i is 0 or 1; j is 0 or 1; k is 0 or 1; Rand Rare in particular H, (C-C)alkyl, or a group of formula C(O)R; R is a, linear or branched, alkyl radical, comprising at least 19 carbon atoms; Ris H and k=0 when j=1; or, when j=0, Ris &#x2014;C(O)R or -L-C(O)R; L, U and L&#x2033; are linkers; wherein, when j=0, at least one of the groups R; Rand Rcomprises a radical R. 

Lipophenol compounds and uses thereof

Growing community of inventors

Montpellier, France

Thierry Durand